

**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 85 to 98 of 2021**

Statements of Principles Nos. 85 to 98 of 2021 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 20 August 2021. The day of commencement as specified in each of these Instruments is 20 September 2021.

These Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from [http://www.legislation.gov.au](http://www.comlaw.gov.au).

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on the Authority's website at http://www.rma.gov.au..

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is also available on the Authority's website at <http://www.rma.gov.au>.

For further information contact:

The Registrar

Repatriation Medical Authority

GPO Box 1014

Brisbane Qld 4001

T +61 7 3815 9404

F +61 7 3815 9412

E info@rma.gov.au

1 September 2021

**SUMMARY OF CHANGES**

|  |  |  |  |
| --- | --- | --- | --- |
| **Instr. No.** | **Title** | **Date of Commencement** | **ICD-10-AM Code** |
| **REPEALS** |
|  |  |  |  |
| 85 & 86/2021 | fibrosing interstitial lung disease  | 20/09/2021 | Nil |
|  |  |  |  |
| 87 & 88/2021 | polycythaemia vera | 20/09/2021 | D45 |
|  |  |  |  |
| 89 & 90/2021 | primary myelofibrosis | 20/09/2021 | Nil |
|  |  |  |  |
| 91 & 92/2021 | essential thrombocythaemia | 20/09/2021 | D47.3 |
|  |  |  |  |
| 93 & 94/2021 | carpal tunnel syndrome | 20/09/2021 | G56.0 |
|  |  |  |  |
| 95 & 96/2021 | myeloma  | 20/09/2021 | C90 |
|  |  |  |  |
| **AMENDMENTS** |
|  |  |  |  |
| 97 & 98/2021 | ischaemic heart disease | 20/09/2021 | I20 to I25 |
|  |  |  |  |

| **SUMMARY OF CHANGES** |
| --- |
| 85 & 86/2021 | fibrosing interstitial lung disease | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning *fibrosing interstitial lung disease* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 85/2021)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'fibrosing interstitial lung disease' in subsection 7(2);
* revising the factors in subsections 9(1) and 9(26) concerning having smoked tobacco products;
* revising the factor in subsection 9(2) concerning inhaling respirable asbestos fibres in an enclosed space, for clinical onset;
* revising the factor in subsection 9(3) concerning inhaling respirable asbestos fibres in an open environment, for clinical onset;
* revising the factors in subsections 9(4) and 9(28) concerning inhaling beryllium dust or fumes, by the inclusion of a note;
* new factors in subsections 9(5) and 9(29) concerning inhaling respirable crystalline silica dust;
* revising the factors in subsections 9(6) and 9(30) concerning having acute silicosis, by the inclusion of a note;
* revising the factors in subsections 9(7) and 9(31) concerning inhaling or intravenously injecting a talc-containing compound or mixture;
* revising the factors in subsections 9(8) and 9(32) concerning inhaling respirable coal dust while engaged in the mining or transport of coal;
* revising the factors in subsections 9(9) and 9(33) concerning inhaling respirable dust generated from hard metal or diamond-cobalt, by the inclusion of a note;
* revising the factors in subsections 9(10) and 9(34) concerning inhaling a toxic gas or fumes;
* revising the factors in subsections 9(11) and 9(35) concerning having paraquat poisoning, by the inclusion of a note;
* revising the factors in subsections 9(13) and 9(37) concerning having received ionising radiation to the lung;
* revising the factors in subsections 9(15) and 9(39) concerning having received iodine-131 (radioactive iodine);
* revising the factors in subsections 9(16) and 9(40) concerning having received yttrium-90 microspheres;
* revising the factors in subsections 9(17) and 9(41) concerning having acute respiratory distress syndrome, by the inclusion of a note;
* revising the factors in subsections 9(19) and 9(43) concerning taking a drug from the specified list of drugs;
* revising the factors in subsections 9(20) and 9(44) concerning having chronic or recurrent diffuse alveolar haemorrhage, by the inclusion of a note;
* revising the factors in subsections 9(21) and 9(45) concerning having exogenous lipoid pneumonitis, by the inclusion of a note;
* revising the factors in subsections 9(22) and 9(46) concerning having tropical pulmonary eosinophilia, by the inclusion of a note;
* new factors in subsections 9(23) and 9(48) concerning inhaling a vapour, gas, dust or fumes produced by a substance from the specified list of substances, or smoke from fire, in an enclosed space;
* new factors in subsections 9(24) and 9(49) concerning inhaling a vapour, gas, dust or fumes produced by a substance from the specified list of substances, or smoke from fire, in an open environment;
* new factors in subsections 9(25) and 9(50) concerning inhaling smoke from the combustion of wood, charcoal, coal or other biomass or fossil fuel, in an enclosed space;
* revising the factor in subsection 9(27) concerning inhaling respirable asbestos fibres, for clinical worsening;
* deleting the factors concerning inhaling respirable crystalline silica dust in an enclosed space and the factors concerning inhaling respirable crystalline silica dust in an open environment, as these have been combined into the factors in subsections 9(5) and 9(29) concerning inhaling respirable crystalline silica dust;
* new definitions of 'acute beryllium disease', 'MRCA', 'one pack-year', 'specified list of drugs', 'specified list of substances' and 'VEA' in
* Schedule 1 - Dictionary;
* revising the definitions of 'acute respiratory distress syndrome', 'acute silicosis', 'diffuse alveolar haemorrhage', 'inhaling beryllium dust or fumes' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a drug or a drug from a class of drugs from the specified list', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'toxic gases or fumes'.

***For BoP SoP (Instrument No. 86/2021)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a date of effect for the Instrument in section 2;
* revising the definition of 'fibrosing interstitial lung disease' in subsection 7(2);
* revising the factors in subsections 9(1) and 9(25) concerning having smoked tobacco products;
* revising the factor in subsection 9(2) concerning inhaling respirable asbestos fibres in an enclosed space, for clinical onset;
* revising the factor in subsection 9(3) concerning inhaling respirable asbestos fibres in an open environment, for clinical onset;
* revising the factors in subsections 9(4) and 9(27) concerning inhaling beryllium dust or fumes, by the inclusion of a note;
* new factors in subsections 9(5) and 9(28) concerning inhaling respirable crystalline silica dust;
* revising the factors in subsections 9(6) and 9(29) concerning having acute silicosis, by the inclusion of a note;
* revising the factors in subsections 9(7) and 9(30) concerning inhaling or intravenously injecting a talc-containing compound or mixture;
* revising the factors in subsections 9(8) and 9(31) concerning inhaling respirable coal dust while engaged in the mining or transport of coal;
* revising the factors in subsections 9(9) and 9(32) concerning inhaling respirable dust generated from hard metal or diamond-cobalt, by the inclusion of a note;
* revising the factors in subsections 9(10) and 9(33) concerning inhaling a toxic gas or fumes;
* revising the factors in subsections 9(11) and 9(34) concerning having paraquat poisoning, by the inclusion of a note;
* revising the factors in subsections 9(13) and 9(36) concerning having received ionising radiation to the lung;
* revising the factors in subsections 9(15) and 9(38) concerning having received iodine-131 (radioactive iodine);
* revising the factors in subsections 9(16) and 9(39) concerning having received yttrium-90 microspheres;
* revising the factors in subsections 9(17) and 9(40) concerning having acute respiratory distress syndrome, by the inclusion of a note;
* revising the factors in subsections 9(19) and 9(42) concerning taking a drug from the specified list of drugs;
* revising the factors in subsections 9(20) and 9(43) concerning having chronic or recurrent diffuse alveolar haemorrhage, by the inclusion of a note;
* revising the factors in subsections 9(21) and 9(44) concerning having exogenous lipoid pneumonitis, by the inclusion of a note;
* revising the factors in subsections 9(22) and 9(45) concerning having tropical pulmonary eosinophilia, by the inclusion of a note;
* new factors in subsections 9(23) and 9(47) concerning inhaling a vapour, gas, dust or fumes produced by a substance from the specified list of substances, or smoke from fire, in an enclosed space;
* new factors in subsections 9(24) and 9(48) concerning inhaling a vapour, gas, dust or fumes produced by a substance from the specified list of substances, or smoke from fire, in an open environment;
* revising the factor in subsection 9(26) concerning inhaling respirable asbestos fibres, for clinical worsening;
* deleting the factors concerning inhaling respirable crystalline silica dust in an enclosed space and the factors concerning inhaling respirable crystalline silica dust in an open environment, as these have been combined into the factors in subsections 9(5) and 9(28) concerning inhaling respirable crystalline silica dust;
* new definitions of 'acute beryllium disease', 'MRCA', 'one pack-year', 'specified list of drugs', 'specified list of substances' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'acute respiratory distress syndrome', 'acute silicosis', 'diffuse alveolar haemorrhage', 'inhaling beryllium dust or fumes' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a drug from the specified list', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'toxic gases or fumes'.

**The determining of these Instruments finalises the investigation in relation to *fibrosing interstitial lung disease* as advertised in the Government Notices Gazette of 5 January 2021.** |
| 87 & 88/2021 | polycythaemia vera | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 23 April 2020 concerning *polycythaemia vera* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH & BoP SoPs*** ***(Instrument No. 87 & 88/2021)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'polycythaemia vera' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* new factor in subsection 9(1) concerning having smoked tobacco products, for clinical onset only;
* new definitions of 'MRCA', 'one pack-year' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary.

**The determining of these Instruments finalises the investigation in relation to *polycythaemia vera* as advertised in the Government Notices Gazette of 23 April 2020.** |
| 89 & 90/2021 | primary myelofibrosis | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 23 April 2020 concerning *primary myelofibrosis* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH & BoP SoPs*** ***(Instrument No. 89 & 90/2021)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'primary myelofibrosis' in subsection 7(2);
* new factor in subsection 9(1) concerning having smoked tobacco products, for clinical onset only;
* new definitions of 'MRCA', 'one pack-year' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definition of 'relevant service' in Schedule 1 - Dictionary.

**The determining of these Instruments finalises the investigation in relation to *primary myelofibrosis* as advertised in the Government Notices Gazette of 23 April 2020.** |
| 91 & 92/2021 | essential thrombocythaemia | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 23 April 2020 concerning *essential thrombocythaemia* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH & BoP SoPs*** ***(Instrument No. 91 & 92/2021)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'essential thrombocythaemia' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* new factor in subsection 9(1) concerning having smoked tobacco products, for clinical onset only;
* new definitions of 'MRCA', 'one pack-year' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definition of 'relevant service'.

**The determining of these Instruments finalises the investigation in relation to *essential thrombocythaemia* as advertised in the Government Notices Gazette of 23 April 2020.** |
| 93 & 94/2021 | carpal tunnel syndrome | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 23 April 2020 concerning *carpal tunnel syndrome* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 93/2021)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'carpal tunnel syndrome' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* new factors in subsections 9(1) and 9(18) concerning performing any combination of specified activities with the affected hand or forearm;
* new factors in subsections 9(2) and 9(19) concerning having trauma or surgery to the affected wrist or hand;
* revising the factors in subsections 9(3) and 9(20) concerning having oedema involving the affected carpal tunnel, by the inclusion of a note;
* revising the factors in subsections 9(4) and 9(21) concerning being overweight or obese;
* revising the factors in subsections 9(5) and 9(22) concerning having amyloidosis, by the inclusion of a note;
* new factors in subsections 9(6) and 9(23) concerning having chronic renal failure;
* revising the factors in subsections 9(7) and 9(24) concerning having hypothyroidism or Hashimoto thyroiditis;
* revising the factors in subsections 9(8) and 9(25) concerning having acromegaly, by the inclusion of a note;
* revising the factors in subsections 9(9) and 9(26) concerning having gout involving the affected wrist or hand;
* revising the factors in subsections 9(10) and 9(27) concerning having a space-occupying lesion in the affected carpal tunnel, by the inclusion of a note;
* revising the factors in subsections 9(11) and 9(28) concerning having haemorrhage involving the affected carpal tunnel, by the inclusion of a note;
* revising the factors in subsections 9(12) and 9(29) concerning having infection involving the affected carpal tunnel, by the inclusion of a note;
* new factors in subsections 9(13) and 9(30) concerning having osteoarthritis or inflammatory arthritis involving the affected wrist or hand;
* revising the factors in subsections 9(15) and 9(32) concerning taking an aromatase inhibitor;
* new factors in subsections 9(16) and 9(33) concerning taking an immune checkpoint inhibitor;
* deleting the factors concerning performing any combination of repetitive activities or forceful activities with the affected hand, as these are now covered by the factors in subsections 9(1) and 9(18) concerning performing any combination of specified activities with the affected hand or forearm;
* deleting the factors concerning performing activities where the affected hand or forearm is directly vibrated, as these are now covered by the factors in subsections 9(1) and 9(18) concerning performing any combination of specified activities with the affected hand or forearm;
* deleting the factors concerning daily self-propulsion of a manual wheelchair, as these are now covered by the factors in subsections 9(1) and 9(18) concerning performing any combination of specified activities with the affected hand or forearm;
* deleting the factors concerning having an injury to the affected wrist or hand which does not involve a fracture or a dislocation, as these are now covered by the factors in subsections 9(2) and 9(19) concerning having trauma or surgery to the affected wrist or hand;
* deleting the factors concerning having a fracture or dislocation to the distal radius, the distal ulna, a carpal bone or a metacarpal bone of the affected side, as these are now covered by the factors in subsections 9(2) and 9(19) concerning having trauma or surgery to the affected wrist or hand;
* deleting the factors concerning having surgery to the affected wrist or hand, as these are now covered by the factors in subsections 9(2) and 9(19) concerning having trauma or surgery to the affected wrist or hand;
* deleting the factors concerning having an external burn involving the affected wrist or palm requiring hospitalisation, as these are now covered by the factors in subsections 9(2) and 9(19) concerning having trauma or surgery to the affected wrist or hand;
* deleting the factors concerning undergoing haemodialysis or peritoneal dialysis, as these are now covered by the factors in subsections 9(6) and 9(23) concerning having chronic renal failure;
* deleting the factors concerning having inflammatory arthritis of the affected wrist or hand, as these are now covered by the factors in subsections 9(13) and 9(30) concerning having osteoarthritis or inflammatory arthritis involving the affected wrist or hand;
* deleting the factors concerning having osteoarthritis of the affected wrist, carpus or trapezio-metacarpal joint of the thumb, as these are now covered by the factors in subsections 9(13) and 9(30) concerning having osteoarthritis or inflammatory arthritis involving the affected wrist or hand;
* new definitions of 'being overweight or obese', 'BMI', 'chronic renal failure', 'MRCA', 'specified activities with the affected hand or forearm', 'trauma to the affected wrist or hand' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'acromegaly', 'amyloidosis', 'inflammatory arthritis' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'aromatase inhibitor', 'being obese', 'forceful activities', 'oedema', 'repetitive activities' and 'space-occupying lesion in the affected carpal tunnel'.

***For BoP SoP (Instrument No. 94/2021)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'carpal tunnel syndrome' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* new factors in subsections 9(1) and 9(17) concerning performing any combination of specified activities with the affected hand or forearm;
* new factors in subsections 9(2) and 9(18) concerning having trauma or surgery to the affected wrist or hand;
* revising the factors in subsections 9(3) and 9(19) concerning having oedema involving the affected carpal tunnel, by the inclusion of a note;
* revising the factors in subsections 9(4) and 9(20) concerning being overweight or obese;
* revising the factors in subsections 9(5) and 9(21) concerning having amyloidosis, by the inclusion of a note;
* new factors in subsections 9(6) and 9(22) concerning having chronic renal failure;
* revising the factors in subsections 9(7) and 9(23) concerning having acromegaly, by the inclusion of a note;
* revising the factors in subsections 9(8) and 9(24) concerning having gout involving the affected wrist or hand;
* revising the factors in subsections 9(9) and 9(25) concerning having a space-occupying lesion in the affected carpal tunnel, by the inclusion of a note;
* revising the factors in subsections 9(10) and 9(26) concerning having haemorrhage involving the affected carpal tunnel, by the inclusion of a note;
* revising the factors in subsections 9(11) and 9(27) concerning having infection involving the affected carpal tunnel, by the inclusion of a note;
* new factors in subsections 9(12) and 9(28) concerning having osteoarthritis or inflammatory arthritis involving the affected wrist or hand;
* revising the factors in subsections 9(14) and 9(30) concerning taking an aromatase inhibitor;
* new factors in subsections 9(15) and 9(31) concerning taking an immune checkpoint inhibitor;
* deleting the factors concerning performing any combination of repetitive activities or forceful activities with the affected hand, as these are now covered by the factors in subsections 9(1) and 9(17) concerning performing any combination of specified activities with the affected hand or forearm;
* deleting the factors concerning performing activities where the affected hand or forearm is directly vibrated, as these are now covered by the factors in subsections 9(1) and 9(17) concerning performing any combination of specified activities with the affected hand or forearm;
* deleting the factors concerning daily self-propulsion of a manual wheelchair, as these are now covered by the factors in subsections 9(1) and 9(17) concerning performing any combination of specified activities with the affected hand or forearm;
* deleting the factors concerning having an injury to the affected wrist or hand which does not involve a fracture or a dislocation, as these are now covered by the factors in subsections 9(2) and 9(18) concerning having trauma or surgery to the affected wrist or hand;
* deleting the factors concerning having a fracture or dislocation to the distal radius, the distal ulna, a carpal bone or a metacarpal bone of the affected side, as these are now covered by the factors in subsections 9(2) and 9(18) concerning having trauma or surgery to the affected wrist or hand;
* deleting the factors concerning having surgery to the affected wrist or hand, as these are now covered by the factors in subsections 9(2) and 9(18) concerning having trauma or surgery to the affected wrist or hand;
* deleting the factors concerning having an external burn involving the affected wrist or palm requiring hospitalisation, as these are now covered by the factors in subsections 9(2) and 9(18) concerning having trauma or surgery to the affected wrist or hand;
* deleting the factors concerning undergoing haemodialysis or peritoneal dialysis, as these are now covered by the factors in subsections 9(6) and 9(22) concerning having chronic renal failure;
* deleting the factors concerning having inflammatory arthritis of the affected wrist or hand, as these are now covered by the factors in subsections 9(12) and 9(28) concerning having osteoarthritis or inflammatory arthritis involving the affected wrist or hand;
* deleting the factors concerning having osteoarthritis of the affected wrist, carpus or trapezio-metacarpal joint of the thumb, as these are now covered by the factors in subsections 9(12) and 9(28) concerning having osteoarthritis or inflammatory arthritis involving the affected wrist or hand;
* deleting the factors concerning having hypothyroidism;
* new definitions of 'being overweight or obese', 'BMI', 'chronic renal failure', 'MRCA', 'specified activities with the affected hand or forearm', 'trauma to the affected wrist or hand' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'acromegaly', 'amyloidosis', 'inflammatory arthritis' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'aromatase inhibitor', 'being obese', 'forceful activities', 'oedema', 'repetitive activities' and 'space-occupying lesion in the affected carpal tunnel'.

**The determining of these Instruments finalises the investigation in relation to *carpal tunnel syndrome* as advertised in the Government Notices Gazette of 23 April 2020.** |
| 95 & 96/2021 | myeloma  | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 23 April 2020 concerning *myeloma* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 95/2021)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'myeloma' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning having received ionising radiation, for clinical onset only, by the inclusion of a note;
* revising the factor in subsection 9(2) concerning inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD), for clinical onset only;
* revising the factor in subsection 9(3) concerning being on land in Vietnam, at sea in Vietnamese waters or on board a vessel and consuming potable water supplied on that vessel, when the water supply had been produced by evaporative distillation of estuarine Vietnamese waters, for clinical onset only, by the inclusion of a note;
* revising the factor in subsection 9(4) concerning having infection with human immunodeficiency virus, for clinical onset only;
* revising the factor in subsection 9(5) concerning undergoing organ or tissue transplantation, excluding corneal transplant and autologous stem cell transplantation, for clinical onset only;
* revising the factor in subsection 9(6) concerning being exposed to benzene as specified, for clinical onset only, by the inclusion of a note;
* revising the factor in subsection 9(7) concerning exposure to benzene, for clinical onset only, by the inclusion of a note;
* revising the factor in subsection 9(8) concerning being obese, by the addition of being overweight, for clinical onset only;
* new factor in subsection 9(9) concerning having an autoimmune disease from the specified list of autoimmune diseases, for clinical onset only;
* deleting the factor concerning working as a painter, for clinical onset only;
* deleting the factor concerning inhaling, ingesting or having cutaneous contact with a phenoxy acid herbicide from the specified list, for clinical onset only;
* deleting the factor concerning having exposure to 2,3,7,8 tetrachlorodibenzo-para-dioxin (TCDD), for clinical onset only;
* new definitions of 'being overweight or obese', 'BMI', 'MRCA', 'organ or tissue transplantation', 'specified list of autoimmune diseases' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'being exposed to benzene as specified' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a phenoxy acid herbicide from the specified list' and 'being obese'.

***For BoP SoP (Instrument No. 96/2021)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'myeloma' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning undergoing organ or tissue transplantation, excluding corneal transplant and autologous stem cell transplantation, for clinical onset only;
* revising the factor in subsection 9(2) concerning being obese, by the inclusion of a note, for clinical onset only;
* deleting the factor concerning having exposure to 2,3,7,8 tetrachlorodibenzo-para-dioxin (TCDD), for clinical onset only;
* deleting the factor concerning being infected with human immunodeficiency virus, for clinical onset only;
* new definitions of 'BMI', 'MRCA', 'organ or tissue transplantation' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definitions of 'being obese' and 'relevant service' in Schedule 1 - Dictionary.

On 22 April 2021, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors from the reasonable hypothesis RH) and balance of probabilities (BoP) Statements of Principles relating to:* *working as a painter for a cumulative period of at least 5000 hours before the clinical onset of myeloma, where the first exposure occurred at least ten years before the clinical onset of myeloma, and where exposure has ceased, the clinical onset of myeloma occurred within 30 years of cessation;* (RH only)
* *inhaling, ingesting or having cutaneous contact with a phenoxy acid herbicide from the specified list, for a cumulative period of at least 1000 hours, within a consecutive period of ten years before the clinical onset of myeloma, where the first exposure occurred at least five years before the clinical onset of myeloma;* (RH only)
* *having exposure to 2,3,7,8 tetrachlorodibenzo-para-dioxin (TCDD) sufficient to produce an expected initial serum TCDD level of at least 1 500 parts per trillion before the clinical onset of myeloma; and* (RH & BoP)
* *being infected with human immunodeficiency virus at the time of the clinical onset of myeloma.* (BoP only)

The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. Minor changes were made to the proposed Instruments following this consultation process.**The determining of these Instruments finalises the investigation in relation to *myeloma* as advertised in the Government Notices Gazette of 23 April 2020.** |
| 97 & 98/2021 | ischaemic heart disease | **Amendment**These instruments amend Statements of Principles Nos. 1 and 2 of 2016 concerning ***ischaemic heart disease*** by:***For RH SoP (Instrument No. 97/2020)**** replacing the existing factors in subsections 9(41) and 9(84) concerning having an autoimmune disease from the specified list of autoimmune diseases;
* deleting the existing definition of 'specified autoimmune collagen vascular disease' in Schedule 1 - Dictionary; and
* inserting a new definition of 'specified list of autoimmune diseases' in Schedule 1 - Dictionary.

***For BoP SoP (Instrument No. 98/2020)**** replacing the existing factors in subsections 9(32) and 9(65) concerning having an autoimmune disease from the specified list of autoimmune diseases;
* deleting the existing definition of 'specified autoimmune collagen vascular disease' in Schedule 1 - Dictionary; and
* inserting a new definition of 'specified list of autoimmune diseases' in Schedule 1 - Dictionary.

**The determining of these Instruments finalises the investigations in relation to *ischaemic heart disease* as advertised in the Government Notices Gazette of 1 June 2021.** |